
BIOGRAPHICAL SKETCH (Update on 10 Nov 2017)

NAME: Emeritus Professor Suwat Chariyalertsak

POSITION TITLE: Dean of Faculty of Public Health, Chiang Mai University, Thailand, and PI of THAI CTU and CMU HIV Prevention Clinical Research Site, Research Institute for Health Sciences, Chiang Mai University, Thailand, Professor of Community Medicine

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
Mahidol University, Bangkok Thailand	M.D.	03/1980	Medicine
Mahidol University, Bangkok Thailand	M.Sc.	04/1987	Clinical Tropical Medicine
Sukhothai Thammathiraj University, Thailand	B.A.	04/1987	Law
Thai Medical Council, Thailand	Thai Board of Preventative Medicine	08/1987	Preventive Medicine
Tulane University, New Orleans, LA	M.P.H.	06/1992	Health System Management
Johns Hopkins University, Baltimore, MD	Dr.PH	06/96	Infectious Disease Epidemiology

OFFICE: Faculty of Public Health, Chiang Mai University, Chiang Mai, 50200, Thailand**PHONE:** +66-53-942504**E-MAIL:** suwat.c@cmu.ac.th and suwat@rihes.org**A. Personal Statement**

I am currently the Dean of Faculty of Public Health, Chiang Mai University and also the Co-PIs for Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI-CTU) which is a consortium comprised of the Chiang Mai University Research Institute for Health Sciences (CMU-RIHES) and the Thai Red Cross AIDS Research Center (TRC-ARC) a component of the Thai Red Cross Society that received 7 years (2013-2020) awarded from the National Institute of Health, USA. I have had experiences with several internationally-funded clinical trials and community studies related to HIV prevention. Additionally, I ever worked as a medical doctor with an appointment as Professor in the Department of Community Medicine at the Chiang Mai University Faculty of Medicine. I have foreign training in public health with an MPH of Health System Management from Tulane University and a DrPH in Infectious Disease Epidemiology from Johns Hopkins University. I am now working as a foundation dean of Faculty of Public Health, Chiang Mai University that just newly opened in April 2017 and also overseeing a number of research staff and dozens of research studies. In this capacity, I have helped train and mentor staff interested in public health research.

B. Positions and Honors**Positions and Employment**

1980 - 1981	Director, Hod Community Hospital, Ministry of Public Health
1981 - 1983	Director, Nong Song Hong Community Hospital, Ministry of Public Health
1983 - 1987	Physician, Department of Preventive Medicine, Nakorn Ping Hospital, Chiang Mai
1996 - 1998	Chairman, Department of Community Medicine, Faculty of Medicine, Chiang Mai University
1998 - 2002	Associate Dean, Policy and Planning, Faculty of Medicine, Chiang Mai University
1988 - 2009	Associate Professor, Department of Community Medicine, Faculty of Medicine, Chiang Mai University
2002 - 2009	Deputy Director, Research Institute for Health Sciences, Chiang Mai University,
2009 – present	Professor, Department of Community Medicine, Faculty of Medicine, Chiang Mai University

2009 - 2017 Director, Research Institute for Health Sciences (RIHES), CMU, Chiang Mai, Thailand
 2013 – Present PI of THAI CTU and CMU HIV Prevention Clinical Research Site, Thailand
 2017 – Present Dean of Faculty of Public Health, Chiang Mai University, Thailand

Other Selected Experience and Professional Membership

2010-2011 A member in Technical Review Panel (TRP) on Evaluation of the National AIDS Response in Thailand.
 2010-2012 A member in National Evaluation Task Force on HIV/AIDS committee, under Thai National AIDS Committee.
 2012 Invited as an expert to review and provide the recommendation for Thailand National HIV/AIDS information System by National AIDS Management Center (NAMC)
 2012-2014 An oversight committee of Thailand Global Fund to Fight AIDS TB and Malaria
 2013 – Present Subnational level, The New Biomedical Technologies to Prevent HIV Infection, National AIDS Management Centre, Ministry of Public Health, Thailand
 2013 – Present Prime-Boost HIV Vaccine Development Committee, Ministry of Public Health, Thailand
 2016 - Present Chairman of the Steering Committee for Burden of Disease Policy Development, International Health Policy Program, Ministry of Public Health, Thailand
 2016– Present A committee of working group to develop national guidelines on HIV/AIDS Treatment and Prevention, Ministry of Public Health, Thailand
 2016– Present A committee of working group to develop the HIV/AIDS surveillance system and analysis of HIV epidemiology, Ministry of Public Health, Thailand
 2016– Present A committee of working group for the evaluation of National HIV Prevention Program, Ministry of Public Health, Thailand
 2017- Present A representative member of faculties in the Chiang Mai University Council, Chiang Mai University, Thailand
 2017- Present A member of working group on budget administration for health promotion and prevention strategy under National Health Security Office, regional 1 Chiang Mai, Thailand
 2017- Present A member of national subcommittee (# 6) on Strategic plan for prevention and control of NCDs, Ministry of Public Health, Thailand

C. Expertise

Epidemiology on Infectious diseases and non-infectious diseases, HIV prevention and control trial, Health program evaluation, Health service and system research, etc.

D. Major contributions to Science

1. Prevention of HIV-1 infection with early antiretroviral therapy

I was the site-PI of the landmark study, HPTN 052, which proved that providing early anti-retroviral treatment to the HIV-positive partners of HIV sero-discordant couples would help prevent transmission of HIV to the HIV-negative partners. This important finding has led to the concept of treatment as prevention (TasP) and policy guideline of providing anti-retrovirals at any CD4+ level.

- a. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, **Chariyalertsak S**, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaud H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med* 2011;365:493-505. doi: 10.1056/NEJMoa1105243. PMID: PMC3200068.

2. Preexposure Prophylaxis of HIV using antiretroviral medications

Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition. The iPrEx study found that oral anti-retrovirals (FTC-TDF) provided protection against the acquisition of HIV infection among MSM and TG subjects. RIHES was one of the study site of this multi-centers international trial.

- a. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, **Chariyalertsak S**, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med* 2010;363:2587-99. doi: 10.1056/NEJMoa1011205. PMID: PMC3079639.
- b. Beyrer C, Baral SD, van Griensven F, Goodreau SM, **Chariyalertsak S**, Wirtz AL, Brookmeyer R. Global epidemiology of HIV infection in men who have sex with men. *Lancet* 2012;380:367-77. PMID: PMC3805037.
- c. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, McMahan V, Bushman LR, Casapía M, Montoya-Herrera O, Veloso VG, Mayer KH, **Chariyalertsak S**, Schechter M, Bekker LG, Kallás EG, Grant RM; iPrEx Study Team. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. *Sci Transl Med* 2012;4(151):151ra125. PMID: PMC3721979.

Publications :

More than 80 peer-reviewed journals. See the **List of Published work in My Bibliography:**

<http://www.ncbi.nlm.nih.gov/sites/myncbi/1rl5bGEAkFO5O/bibliography/46581141/public/?sort=date&direction=ascending>

E. Research Support

Ongoing research support

NIH/NIAID UM1 AI 069399

Chariyalertsak, S (PI)

03/15/07 - 01/31/20

Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU)

To conduct clinical trials research aimed at improving prevention and treatment strategies for HIV.

Role: Principal Investigator

Chariyalertsak, S (PI)

05/01/16-30/11/21

HPTN 083: A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men

This study aim to evaluate the efficacy of long acting cabotegravir injection (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected men and transgender women who have sex with men (MSM and TGW) with goal of 4500 participants around the world. At CMU-RIHES, we plan to enroll 177 participants. This protocol shall be activated in the third quarter of 2017.

Role: Principal Investigator

Chariyalertsak, S (PI)

08/01/16-07/31/19

CMU-RIHES

PrEP@PIMAN: Acceptability of HIV Oral Pre-Exposure Prophylaxis (PrEP) Among Men Have Sex with Men (MSM) and Transgender Women (TGW) - NCT02855606

This study aim to determine the factors associated with acceptability to oral HIV pre-exposure prophylaxis (PrEP) among Thai men who have sex with men (MSM) and transgender women (TGW).

Role: Principal Investigator

Completed research support (Selected)

Chariyalertsak, S (PI)

03/01/13 - 11/30/16

The Henry M. Jackson Foundation for the Advancement of Military Medicine W81XWH-11-2-0174

Randomized, Double Blind Evaluation of Different One-Year Boosts after Sanofi Pasteur Live Recombinant VALVAC-HIV (vCP1521) and Global Solutions for Infectious Diseases (GSID) gp120 B/E

(AIDSVAX® B/E) Prime-Boost Regimen in HIV-uninfected Thai Adults

This is a randomized, double-blinded study to evaluate the safety and efficacy of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming and Multiple Boosting Regimens with and without VaxGen gp120 B/E (AIDSVAX® B/E) in HIV-uninfected Thai Adults. It is a follow-up study after RV144 Thai vaccine trial under the US Military HIV Research program (MHRP).

Role: Principal Investigator

U01 MH066687 Celentano, D (PI)

07/01/2003 - 06/30/2011

HPTN 043 : A Phase III Randomized Controlled Trial of Community Mobilization, Mobile testing, Same-Day Results, and Post-Test Support for HIV in Sub-Saharan Africa and Thailand.

This study aimed to assess whether HIV testing could be increased by combination of community mobilisation, mobile community-based voluntary counselling and testing (VCT), and support after testing. Over 20,000 participants were enrolled from Thailand site. Community-based VCT was found to be viable intervention to increase detection of HIV infection.

Role: Co-Principal Investigator

UM1AI068619 Chariyalertsak S (PI)

06/01/09 - 05/31/13

FHI360

HPTN063: Preparing for International Prevention Trials Involving HIV-Infected Individuals In Care Settings

This study aimed to understand the impact of community HIV stigma and gender norms on disclosure among HIV-infected female in different countries.

Role: HPTN Site Leader

Chariyalertsak, S (PI)

06/01/14-07/31/16

HPTN052: A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 In Serodiscordant Couples

This study aimed to evaluate the effect of combination antiretroviral therapy on the prevention of HIV-1 transmission to uninfected partners. The result was satisfying with early initiation of antiretroviral therapy reduced rates of HIV-1 sexual transmission and clinical events. This is one of the landmark studies that support the antiretroviral therapy for "all CD4" strategy.

Role: Principal Investigator

R8098-C Chariyalertsak, S (PI)

10/01/07-01/31/11

NIH/NIAID with Co-funding from The Bill and Melinda Gates foundation

iPrEx: Chemoprophylaxis for HIV Prevention in Men

Phase III randomized, double-blind, placebo controlled trial studied the safety and efficacy of taking Truvada (emtricitabine/tenofovir disoproxil fumarate) to prevent HIV infection

Role: Principal Investigator

Chariyalertsak, S (PI)

09/01/12-07/31/15

Chemaprophylaxis for HIV Prevention in Men Open Label Extension (iPEX-OLE)

This was an open-label extension phase from iPrEx study. It aim to provide additional information about the safety of PrEP and the behavior of people taking PrEP over a longer term.

Role: Principal Investigator

Miura, T (PI)

09/01/12-12/31/15

Grants-in-Aid for Scientific Research (B) for oversee investigation by Japan Society for the Promotion of Science

Molecular Epidemiology of HPV in MSM in Northern Thailand

This study aimed to explore the prevalence of HPV among gay men, bisexual men, and transgender women in northern Thailand.

Role: Principal Investigator